Breast Cancer Clinical Trials in Ventura, CA

Breast Cancer Clinical Trials in Ventura, CA

View the best 10 breast cancer medical studies in Ventura, California. Access promising new therapies by applying to a Ventura-based Breast Cancer clinical trial.

Trials in Ventura, California

Here are the top 10 medical studies for breast cancer in Ventura, California

Image of Arizona Oncology Associates, PC-Hope in Tucson, United States.

Sacituzumab Govitecan-hziy

Monoclonal Antibodies

Recruiting4 awardsPhase 3
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Image of CBCC Global Research Inc., at Comprehensive Blood and Cancer Center in Bakersfield, United States.

Endocrine Therapy of Physician's Choice +1 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Image of Alaska Oncology and Hematology in Anchorage, United States.

Sacituzumab Govitecan-hziy +1 More

Antibody-Drug Conjugate

Recruiting4 awardsPhase 3
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Image of University of Kansas Cancer Center in Kansas City, United States.

Paclitaxel +4 More

Anti-microtubule agents

Recruiting2 awardsPhase 3
This trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Image of Lakeland Regional Cancer Center in Lakeland, United States.

ARV-471

Hormone Therapy

Recruiting2 awardsPhase 3
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Image of START Midwest in Grand Rapids, United States.

BBI-355

Checkpoint Inhibitor

Recruiting1 awardPhase 1
This trial is researching a potential new cancer treatment to see how safe and effective it is.
Image of King Regional Medical Center in Kingman, United States.

Chemotherapy

Recruiting1 awardPhase 2
This trial tests an imaging procedure in patients with a specific type of breast cancer. The test uses a small amount of radioactive sugar to highlight active cancer areas, helping doctors decide if more or less treatment is needed before surgery. This imaging procedure has been used successfully for diagnosis, initial staging, restaging, early treatment response assessment, evaluation of disease spread, and predicting outcomes in breast cancer.
Image of Boca Raton Regional Hospital in Boca Raton, United States.

MDNA11

Interleukin-2 (IL-2) Agonist

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug to treat cancer. The drug is given alone or with another drug. The study will see how well the drug works and how safe it is.
Image of University of Alabama at Birmingham in Birmingham, United States.

Gedatolisib +2 More

PI3K/mTOR Inhibitor

Recruiting2 awardsPhase 3
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Image of Research Site in Duarte, United States.

Dato-DXd

Antibody-Drug Conjugate

Recruiting2 awardsPhase 3
This trial is testing a new drug called datopotamab deruxtecan to see if it helps patients with advanced breast cancer live longer or have a better quality of life compared to standard chemotherapy. Datopotamab deruxtecan has shown encouraging response rates and manageable toxicity in patients with advanced/metastatic triple-negative breast cancer.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.